Source-grounded facts extracted from Sigyn Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Sigyn Therapeutics, Inc. entered into Convertible Note Purchase Agreement with Lambda Venture Partners, LLC valued at $27,777.77 (effective 2026-02-06).
“On February 6, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Lambda Venture Partners, LLC, in the principal amount of $27,777.77”
Sigyn Therapeutics, Inc. entered into Convertible Note Purchase Agreement with Osher Capital Partners, LLC valued at $22,222.22 (effective 2026-02-12).
“On February 12, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Osher Capital Partners, LLC, in the principal amount of $22,222.22”
Sigyn Therapeutics, Inc. entered into Convertible Note Purchase Agreement with Brio Capital Master Fund, Ltd valued at $22,222.22 (effective 2026-02-12).
“On February 12, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Brio Capital Master Fund, Ltd, in the principal amount of $22,222.22”
James Joyce was appointed as interim Chief Financial Officer at Sigyn Therapeutics, Inc..
“Mr. James Joyce, our Chief Executive Officer, will serve as our interim Chief Financial Officer.”
Gerald DeCiccio retired as Chief Financial Officer at Sigyn Therapeutics, Inc..
“On February 26, 2025, our Chief Financial Officer, Mr. Gerald DeCiccio provided us a notice of retirement, effective immediately.”
Michael Ryan was appointed as Director at Sigyn Therapeutics, Inc..
“On January 11, 2025, our Board of Directors appointed Michael Ryan to our Board of Directors.”
Sigyn Therapeutics, Inc. amended Debentures with Brio Capital Master Fund Ltd. and Osher Capital Partners, LLC valued at $110,000 and $275,000 (effective 2024-04-10).
“Brio and Osher agreed to amend an additional $110,000 and $275,000, respectively, of Debentures to extend the maturity dates of such Debentures to March 31, 2025 in return for an increase in principal amount of such Debentures to $125,000 and $316,350”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.